SNIPR001 CRISPR-Armed Phage Therapy Shrinks Drug-Resistant E. coli Mass by 89% in Compassionate-Use Case

SNIPR Biome (Copenhagen) published a peer-reviewed expanded-access case report in Clinical Infectious Diseases describing use of SNIPR001, a CRISPR-armed bacteriophage medicine, in a 65-year-old kidney transplant recipient with progressive, multidrug-resistant Escherichia coli malakoplakia treated under emergency compassionate use outside SNIPR001's ongoing gut-focused Phase 1b/2a trial (NCT06938867). Within one week of initiation the patient's abdominal cutaneous lesions improved markedly, with several fully healed by four weeks; imaging showed the intra-abdominal mass shrank from 744.6 cm³ at baseline to 373.4 cm³ at week eight and to 82 cm³ after a year — an 89% reduction. Researchers caution the single case cannot establish causation, but it is the first look at the CRISPR-guided phage therapy acting directly against an established extra-intestinal infection.